CTLA4 and hepatocellular carcinoma: According to available evidence, TRAEs are reported in over 90% of HCC patients receiving anti-CTLA-4 antibodies and 70% of patients treated with PD-1 and PD-L1 inhibitors, with the most common types being gastrointestinal, endocrine, and cutaneous [110,111,112,113].